DETECTION AND QUANTITATION OF FUSION MRNAS IN LEUKEMIA

白血病融合 MRNAS 的检测和定量

• 批准号: 6015574
• 负责人: MARIANNA Mansfield GOLDRICK
• 金额: $ 10.34万
• 依托单位: AMBION, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-01 至 2000-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6015574
• 关键词: DNA primers; cell line; diagnosis design /evaluation; diagnostic tests; fusion gene; leukemia; messenger RNA; minimal residual disease; molecular oncology; neoplasm /cancer diagnosis; neoplastic cell; nucleic acid probes; nucleic acid quantitation /detection; oligonucleotides; polymerase chain reaction

The proposed work will result in diagnostic kits and assays for rapid high throughput detection and monitoring of abnormal mRNAs associated with leukemia. Hybridization-based molecular as says will be developed for rapid characterization of translocations involved in hematologic malignancies. The ability to more rapidly determine the particular translocation involved in a patient's leukemia will permit faster initiation of therapy at the time of initial diagnosis. Sensitive quantitative methods will also be developed for assessing amplified fusion mRNAs using a novel relative quantitative RT- PCR strategy. Improved assays able to provide quantitative values for fusion mRNAs will aid clinicians in determining the most effective treatment for leukemia patients at risk for relapse. The proposed assays will have a reduced chance of generating erroneous results due to sample cross-contamination, because they will provide the requisite sensitivity needed to detect minimal residual disease without the need to use sequential exponential amplification strategies, which are highly prone to contamination. The homogenous, non- gel-based as says proposed will have a reduced cost and faster turnaround time compared to current gel-based methods, which will result in cost-savings to the healthcare system as well as benefits to the patient. PROPOSED COMMERCIAL APPLICATIONS: Kits containing reagents and protocols to identify and monitor genetic abnormalities associated with leukemia and other cancers will be developed. The kits will be marketed by Ambion for use in both research and diagnostic settings.

拟议的工作将产生诊断试剂盒和检测方法，用于快速高通量检测和监测与白血病相关的异常 mRNA。据称，基于杂交的分子将被开发用于快速表征血液恶性肿瘤中涉及的易位。更快速地确定患者白血病所涉及的特定易位的能力将允许在初始诊断时更快地开始治疗。还将开发灵敏的定量方法，使用新型相对定量 RT-PCR 策略评估扩增的融合 mRNA。能够提供融合 mRNA 定量值的改进检测将帮助临床医生确定针对有复发风险的白血病患者的最有效治疗方法。所提出的检测方法将减少因样品交叉污染而产生错误结果的机会，因为它们将提供检测最小残留疾病所需的灵敏度，而无需使用极易受到污染的顺序指数扩增策略。与当前基于凝胶的方法相比，所提出的均质非凝胶方法将具有更低的成本和更快的周转时间，这将节省医疗保健系统的成本并为患者带来好处。拟议的商业应用：将开发包含试剂和方案的试剂盒，用于识别和监测与白血病和其他癌症相关的遗传异常。这些试剂盒将由 Ambion 销售，用于研究和诊断环境。